AC Immune SA develops precision therapeutics and diagnostics for neurodegenerative diseases driven by misfolded proteins. The clinical-stage biopharmaceutical company uses its SupraAntigen® and Morphomer® platforms to advance active immunotherapies, small molecules, antibodies, vaccines and diagnostic programs for Alzheimer’s disease, Parkinson’s disease and NeuroOrphan indications.
Company news commonly covers clinical updates for ACI-24 in the ABATE Alzheimer’s disease study, ACI-7104.056 in the VacSYn Parkinson’s disease trial, ACI-19764 as an NLRP3 inflammasome inhibitor, and Tau Morphomer® small-molecule programs. Updates also include collaboration activity with global pharmaceutical partners, milestone payments, symposium presentations, financial results and cash runway disclosures.
AC Immune (NASDAQ: ACIU) dosed the first patient in Cohort AD4 of the Phase 1b/2 ABATE trial and triggered a $12 million milestone from Takeda. AD4 will enroll 36 patients for 12 months (plus 6-month follow-up) and could expand to ~112 patients. 12-month data from AD1–AD3 are expected in Q2 2026. Under the Takeda agreement, AC Immune received a $100 million upfront payment and is eligible for up to $2.1 billion in further milestones and tiered double-digit royalties on sales.
AC Immune (NASDAQ: ACIU) amended its 2018 Morphomer Tau license and collaboration with Eli Lilly to advance orally bioavailable Tau aggregation inhibitor small molecules.
The amendment includes a CHF10 million upfront payment, an additional Phase 1 dosing milestone, IND-enabling studies starting H1 2026, eligibility for >CHF1.7 billion in milestones, and low double-digit tiered royalties.
AC Immune (NASDAQ: ACIU) presented Phase 1 data March 19, 2026 showing the first in vivo PET images of TDP-43 brain pathology using tracer ACI-19626. Initial scans showed significantly higher tracer uptake in key cortical and subcortical regions of C9orf72 genetic FTD patients versus healthy subjects.
ACI-19626 demonstrated good safety, acceptable dosimetry, and a PK profile with rapid brain uptake and washout. Part 1 final data expected H1 2026; Part 2 expansion is underway to study additional patient populations including ALS and LATE.
AC Immune (NASDAQ: ACIU) reported full-year 2025 results and a corporate update. Key items: interim Phase 2 VacSYn data suggest ACI-7104 may slow Parkinson’s progression and showed 100% immunogenic responder rate. Cash was CHF 91.4M at Dec 31, 2025, extending runway to Q3 2027. The company reported a net loss of CHF 70.5M and expects 2026 cash expenditure of CHF 55–65M. Management reduced workforce by ~30% and advanced ACI-19764 into Phase 1.
AC Immune (NASDAQ: ACIU) will host an industry symposium on Parkinson’s disease and present a first-in-class TDP-43 PET-tracer at AD/PD™ 2026 in Copenhagen, March 17–21, 2026. The symposium on March 18 highlights a precision prevention approach and features data updates, scientific talks, and a Q&A session.
Oral presentation of [18F]ACI-19626 is scheduled for March 19, focusing on biomarker pathways linking amyloid, tau, and neurodegeneration. A symposium replay will be available on the company events page.
AC Immune (NASDAQ: ACIU) has dosed the first participant in a Phase 1 trial of ACI-19764, an oral, brain-penetrant NLRP3 inhibitor. The study in healthy volunteers will assess safety, tolerability, PK/PD, and target engagement, with initial Phase 1 data expected in H2 2026.
Preclinical results reportedly show high potency, CNS penetrance, and reduced neuroinflammation in vivo, positioning ACI-19764 as a competitive candidate for neurodegenerative and inflammatory indications.
AC Immune (NASDAQ: ACIU) reported positive interim Phase 2 VacSYn results for its active immunotherapy ACI-7104.056 in early Parkinson’s disease on December 11, 2025. Part 1 (34 patients, randomized 3:1) reached all immunogenicity targets with a 100% responder rate and serum/CSF antibody titers >500-fold versus placebo. Biomarkers showed stabilization: total CSF a-syn (post-hoc p=0.018), CSF NfL, plasma GFAP trends, and DaT SPECT signals. MDS-UPDRS Part III scores suggested motor stabilization. Safety was favorable with no drug-related serious AEs; most common AEs were injection site reactions (56%), headache (15%), fatigue (12%). Final Part 1 data expected mid-2026.
AC Immune (NASDAQ: ACIU) will participate in the Jefferies 2025 London Healthcare Conference, November 17-20, 2025.
Management will take part in a fireside chat on November 18, 2025 at 4:30 AM ET / 9:30 AM GMT and will hold one-on-one investor meetings. A live webcast of the fireside chat will be available on the company Events Page, and a replay will be archived there. Investors should contact their Jefferies representative to request meetings with management during the conference.
AC Immune (NASDAQ: ACIU) reported Q3 2025 results and a corporate update on November 4, 2025. The company holds CHF 108.5 million in cash resources as of September 30, 2025 (CHF 27.7M cash and CHF 80.7M short-term assets) and said this provides funding to the end of Q3 2027 excluding milestone income. Management narrowed investment focus to three Phase 2 active immunotherapies and small-molecule programs (NLRP3, Tau, a-syn), reduced workforce by ~30%, and recognized CHF 0.5M restructuring expenses.
Near-term milestones expected in Q4 2025 include IND/CTA filing for ACI-19764, lead declarations and IND-enabling starts for Morphomer programs, and multiple Phase 1/2 readouts and interim Part 1 VacSYn results.
AC Immune (NASDAQ: ACIU) appointed Prof. Catherine Mummery as Chair of its Clinical Advisory Board effective October 28, 2025.
Prof. Mummery leads cognitive disorders at NHNN and novel therapeutics at UCL, has been senior investigator on more than 20 early-stage studies, led the first clinical trial of a Tau gene‑silencing therapy, and served as an investigator on AC Immune’s Phase 1b/2a ACI-35.030 (JNJ-2056) study.
The CAB advises on clinical development and regulatory strategy; other members include Reisa Sperling, Murat Emre, Lon Schneider, Pierre Tariot, and Juan Fortea. Dr. Kaj Blennow is retiring from the CAB.